All Stories

  1. International Union of Basic and Clinical Pharmacology. XXXX. Apelin Receptor Pharmacology in the Human Cardiovascular System and Emerging Clinical Applications.
  2. The Concise Guide to PHARMACOLOGY 2025/26: G protein‐coupled receptors
  3. The Concise Guide to PHARMACOLOGY 2025/26: Introduction and Other Protein Targets
  4. Bile acid receptor in GtoPdb v.2025.3
  5. Chemerin receptors in GtoPdb v.2025.3
  6. Ghrelin receptor in GtoPdb v.2025.3
  7. Succinate receptor in GtoPdb v.2025.3
  8. Trace amine receptor in GtoPdb v.2025.3
  9. Apelin receptor in GtoPdb v.2025.3
  10. Endothelin receptors in GtoPdb v.2025.3
  11. Short communications: Endothelin-1 in cardiac allograft vasculopathy
  12. Cardiovascular and renal effects of apelin in chronic kidney disease: a randomised, double-blind, placebo-controlled, crossover study
  13. Microarray analysis demonstrates up-regulation of the endothelin-1 gene with compensatory down-regulation of the ETA receptor gene in human portal vein
  14. Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together?
  15. Co-localization of the sodium-glucose co-transporter-2 channel (SGLT-2) with endothelin ETA and ETB receptors in human cardiorenal tissue
  16. Structural and functional determination of peptide versus small molecule ligand binding at the apelin receptor
  17. Targeting the apelin system for the treatment of cardiovascular diseases
  18. Current and future strategies for targeting the endothelin pathway in cardiovascular disease
  19. The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
  20. Urotensin receptor in GtoPdb v.2023.1
  21. Trace amine receptor in GtoPdb v.2023.1
  22. Thyrotropin-releasing hormone receptors in GtoPdb v.2023.1
  23. Class A Orphans in GtoPdb v.2023.1
  24. Motilin receptor in GtoPdb v.2023.1
  25. Neuropeptide W/neuropeptide B receptors in GtoPdb v.2023.1
  26. Endothelin receptors in GtoPdb v.2023.1
  27. Kisspeptin receptor in GtoPdb v.2023.1
  28. Succinate receptor in GtoPdb v.2023.1
  29. Apelin receptor in GtoPdb v.2023.1
  30. Bile acid receptor in GtoPdb v.2023.1
  31. QRFP receptor in GtoPdb v.2023.1
  32. Ghrelin receptor in GtoPdb v.2023.1
  33. Chemerin receptors in GtoPdb v.2023.1
  34. Oxoglutarate receptor in GtoPdb v.2023.1
  35. Class A Orphans in GtoPdb v.2022.3
  36. Trans-myocardial Extraction of Endothelin-1 Correlates with Increased Microcirculatory Resistance following Percutaneous Coronary Intervention
  37. In vitro metabolism of synthetic Elabela/Toddler (ELA-32) peptide in human plasma and kidney homogenates analyzed with mass spectrometry and validation of endogenous peptide quantification in tissues by ELISA
  38. The IUPHAR/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials
  39. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
  40. Class A Orphans in GtoPdb v.2021.3
  41. Urotensin receptor in GtoPdb v.2021.3
  42. Succinate receptor in GtoPdb v.2021.3
  43. Ghrelin receptor in GtoPdb v.2021.3
  44. Chemerin receptors in GtoPdb v.2021.3
  45. The therapeutic potential of apelin in kidney disease
  46. Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infection
  47. Motilin receptor in GtoPdb v.2021.2
  48. Human embryonic stem cell-derived cardiomyocytes express SARS-CoV-2 host entry proteins: screen to identify inhibitors of infection
  49. Class A Orphans (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database
  50. Motilin receptor (version 2020.4) in the IUPHAR/BPS Guide to Pharmacology Database
  51. Kisspeptin receptor (version 2020.4) in the IUPHAR/BPS Guide to Pharmacology Database
  52. Genes Encoding ACE2, TMPRSS2 and Related Proteins Mediating SARS-CoV-2 Viral Entry are Upregulated with Age in Human Cardiomyocytes
  53. A rational roadmap for SARS‐CoV‐2/COVID‐19 pharmacotherapeutic research and development. IUPHAR Review 29
  54. Advances in therapeutic peptides targeting G protein-coupled receptors
  55. Class A Orphans (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database
  56. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors
  57. Apelin-36-[L28A] and Apelin-36-[L28C(30kDa-PEG)] peptides that improve diet induced obesity are G protein biased ligands at the apelin receptor
  58. QRFP receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  59. Class A Orphans (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  60. Bile acid receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  61. Apelin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  62. Oxoglutarate receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  63. Chemerin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  64. Ghrelin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  65. Endothelin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  66. Kisspeptin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  67. Motilin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  68. Neuropeptide W/neuropeptide B receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  69. Succinate receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  70. Thyrotropin-releasing hormone receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  71. Trace amine receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  72. Urotensin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  73. International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand
  74. International Union of Basic and Clinical Pharmacology CIII: Chemerin Receptors CMKLR1 (Chemerin1) and GPR1 (Chemerin2) Nomenclature, Pharmacology, and Function
  75. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors
  76. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview
  77. Pharmacological targeting of apelin impairs glioblastoma growth
  78. Detection of Atherosclerotic Inflammation by 68 Ga-DOTATATE PET Compared to [ 18 F]FDG PET Imaging
  79. Vascular Imaging With 18 F-Fluorodeoxyglucose Positron Emission Tomography Is Influenced by Hypoxia
  80. 18 F-Fluoride and 18 F-Fluorodeoxyglucose Positron Emission Tomography After Transient Ischemic Attack or Minor Ischemic StrokeCLINICAL PERSPECTIVE
  81. [Pyr1]Apelin-13(1–12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13
  82. Elabela/Toddler Is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of Its Expression in Pulmonary Arterial HypertensionClinical Perspective
  83. OUP accepted manuscript
  84. Smooth Muscle Endothelin B Receptors Regulate Blood Pressure but Not Vascular Function or Neointimal RemodelingNovelty and Significance
  85. Chemerin Elicits Potent Constrictor Actions via Chemokine‐Like Receptor 1 (CMKLR1), not G‐Protein‐Coupled Receptor 1 (GPR1), in Human and Rat Vasculature
  86. Cardiac action of the first G protein biased small molecule apelin agonist
  87. Endothelin ETA receptors predominate in chronic thromboembolic pulmonary hypertension
  88. The endothelin hormones, structure and function
  89. The Prodomain-bound Form of Bone Morphogenetic Protein 10 Is Biologically Active on Endothelial Cells
  90. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors
  91. The Concise Guide to PHARMACOLOGY 2015/16: Overview
  92. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands
  93. Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system
  94. Identifying active vascular microcalcification by 18F-sodium fluoride positron emission tomography
  95. LGR5 Activates Noncanonical Wnt Signaling and Inhibits Aldosterone Production in the Human Adrenal
  96. Endothelin Receptors and Their Antagonists
  97. Design, Characterization, and First-In-Human Study of the Vascular Actions of a Novel Biased Apelin Receptor Agonist
  98. Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12
  99. Changes in biomechanical properties of the coronary artery wall contribute to maintained contractile responses to endothelin-1 in atherosclerosis
  100. Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension
  101. In Vivo Mapping of Vascular Inflammation Using the Translocator Protein Tracer 18 F-FEDAA1106
  102. Characterization of [125I]GLP-1(9-36), a novel radiolabeled analog of the major metabolite of glucagon-like peptide 1 to a receptor distinct from GLP1-R and function of the peptide in murine aorta
  103. The CCR5 chemokine receptor mediates vasoconstriction and stimulates intimal hyperplasia in human vessels in vitro
  104. The Concise Guide to PHARMACOLOGY 2013/14: Overview
  105. The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands
  106. Evolving pharmacology of orphan GPCRs: IUPHAR Commentary
  107. No evidence for a local renin-angiotensin system in liver mitochondria
  108. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension
  109. Screening β-Arrestin Recruitment for the Identification of Natural Ligands for Orphan G-Protein–Coupled Receptors
  110. International Union of Basic and Clinical Pharmacology. LXXXVIII. G Protein-Coupled Receptor List: Recommendations for New Pairings with Cognate Ligands
  111. Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer
  112. Themed section: endothelin
  113. IUPHAR-DB: updated database content and new features
  114. The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans
  115. Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice
  116. Comparison of human ETA and ETB receptor signalling via G-protein and β-arrestin pathways
  117. Defining the affinity and receptor sub-type selectivity of four classes of endothelin antagonists in clinically relevant human cardiovascular tissues
  118. The Twelfth International Conference on Endothelin (ET-12), Cambridge 2011
  119. GuideToPharmacology.org - an update
  120. Cellular Localization of Receptors Using Antibodies Visualized by Light and Dual Labeling Confocal Microscopy
  121. Dynamic In Vivo Imaging of Receptors in Small Animals Using Positron Emission Tomography
  122. How to Use the IUPHAR Receptor Database to Navigate Pharmacological Data
  123. Quantitative Phosphor Imaging Autoradiography of Radioligands for Positron Emission Tomography
  124. Radioligand Binding Assays and Their Analysis
  125. Receptor Binding Techniques
  126. Inotropic Action of the Puberty Hormone Kisspeptin in Rat, Mouse and Human: Cardiovascular Distribution and Characteristics of the Kisspeptin Receptor
  127. Importance of Subtype Selectivity for Endothelin Receptor Antagonists in the Human Vasculature
  128. Discovery of a Competitive Apelin Receptor (APJ) Antagonist
  129. Chemokine receptor CCR5: from AIDS to atherosclerosis
  130. Pharmacology of Renal Endothelin Receptors
  131. International Union of Basic and Clinical Pharmacology. LXXVII. Kisspeptin Receptor Nomenclature, Distribution, and Function
  132. Evidence for a novel vasospastic transmitter system, neuromedin U, in the equine digital circulation
  133. International Union of Basic and Clinical Pharmacology. LXXIV. Apelin Receptor Nomenclature, Distribution, Pharmacology, and Function
  134. Endothelial cell-specific ETBreceptor knockout: autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1This article is one of a selection of papers published in the two-part special issue entitled 20 Years o...
  135. Evaluation of translocator protein quantification as a tool for characterising macrophage burden in human carotid atherosclerosis
  136. Introduction
  137. Modulation of the apelin/APJ system in heart failure and atherosclerosis in man
  138. Positron emission tomography of [18F]-big endothelin-1 reveals renal excretion but tissue-specific conversion to [18F]-endothelin-1 in lung and liver
  139. EDITORIAL
  140. The endothelin system in pulmonary and renal vasculopathy: les liaisons dangereuses
  141. FDG–PET can distinguish inflamed from non-inflamed plaque in an animal model of atherosclerosis
  142. Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S
  143. [Pyr1]Apelin-13 Identified as the Predominant Apelin Isoform in the Human Heart: Vasoactive Mechanisms and Inotropic Action in Disease
  144. International Union of Pharmacology. LXXII. Recommendations for Trace Amine Receptor Nomenclature
  145. Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation
  146. Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system
  147. Positron emission tomography using 18F-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ETB receptors in vivo
  148. Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular system
  149. IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels
  150. Automated synthesis of the generic peptide labelling agent N-succinimidyl 4-[18F]fluorobenzoate and application to 18F-label the vasoactive transmitter urotensin-II as a ligand for positron emission tomography
  151. Chronic Apoptosis of Vascular Smooth Muscle Cells Accelerates Atherosclerosis and Promotes Calcification and Medial Degeneration
  152. Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: Relevance to function
  153. Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease
  154. Strategy for improved [11C]DAA1106 radiosynthesis and in vivo peripheral benzodiazepine receptor imaging using microPET, evaluation of [11C]DAA1106
  155. Kisspeptins Are Novel Potent Vasoconstrictors in Humans, with a Discrete Localization of Their Receptor, G Protein-Coupled Receptor 54, to Atherosclerosis-Prone Vessels
  156. Endothelin Receptors
  157. Urotensin-II Receptor
  158. ET-B Endothelin Receptor
  159. ET-A Endothelin Receptor
  160. Characterization of the snake venom ligand [125I]-DNP binding to natriuretic peptide receptor-A in human artery and potent DNP mediated vasodilatation
  161. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis
  162. Neuropeptide B and W: neurotransmitters in an emerging G-protein-coupled receptor system
  163. Novel Snake Venom Ligand Dendroaspis Natriuretic Peptide Is Selective for Natriuretic Peptide Receptor-A in Human Heart: Downregulation of Natriuretic Peptide Receptor-A in Heart Failure
  164. Deletion of Endothelial Cell Endothelin B Receptors Does Not Affect Blood Pressure or Sensitivity to Salt
  165. Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man
  166. International Union of Pharmacology. LVI. Ghrelin Receptor Nomenclature, Distribution, and Function
  167. Triptan-induced contractile (5-HT1Breceptor) responses in human cerebral and coronary arteries: relationship to clinical effect
  168. Emerging roles of apelin in biology and medicine
  169. Regulation of vascular reactivity by established and emerging GPCRs
  170. International Union of Pharmacology. XLVI. G Protein-Coupled Receptor List
  171. Receptor Binding Techniques
  172. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells
  173. Alternative Pathway to Endothelin-Converting Enzyme for the Synthesis of Endothelin in Human Blood Vessels
  174. Comparison of Endothelin-A and Endothelin-B Receptor Distribution Visualized by Radioligand Binding versus Immunocytochemical Localization using Subtype Selective Antisera
  175. Down-regulation of ETA Receptors in ETB Receptor-deficient Mice
  176. Endothelin Receptor Pharmacology and Function in the Mouse: Comparison with Rat and Man
  177. In Vivo Imaging of Cardiovascular Endothelin Receptors Using the Novel Radiolabelled Antagonist [18F]-SB209670 and Positron Emission Tomography (microPET)
  178. CRF2receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators
  179. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries
  180. Regional Hemodynamic Actions of Selective Corticotropin-Releasing Factor Type 2 Receptor Ligands in Conscious Rats
  181. Identification and cellular localisation of NPW1 (GPR7) receptors for the novel neuropeptide W-23 by [125I]-NPW radioligand binding and immunocytochemistry
  182. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells
  183. Maternal Dexamethasone Increases Endothelin-1 Sensitivity and Endothelin A Receptor Expression in Ovine Foetal Placental Arteries
  184. Peptide and trace amine orphan receptors: prospects for new therapeutic targets
  185. Translating the human genome: renaissance of cardiovascular receptor pharmacology
  186. Emerging roles for orphan G-protein-coupled receptors in the cardiovascular system
  187. Life before birth: effects of cortisol on future cardiovascular and metabolic function*
  188. Is urotensin-II the new endothelin?
  189. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1
  190. Peptide Research Protocols
  191. International Union of Pharmacology. XXIX. Update on Endothelin Receptor Nomenclature
  192. Imaging Atherosclerotic Plaque Inflammation With [18F]-Fluorodeoxyglucose Positron Emission Tomography
  193. Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system
  194. Of mice and men: advances in endothelin research and first antagonist gains FDA approval
  195. Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors
  196. Radioligand binding reveals chymase as the predominant enzyme for mediating tissue conversion of angiotensin I in the normal human heart
  197. Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT1receptor antagonist losartan
  198. Vasoconstrictor activity of novel endothelin peptide, ET-1(1 - 31), in human mammary and coronary arteriesin vitro
  199. [125I-His9]-Ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue; up-regulation of receptors with atherosclerosis
  200. Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery
  201. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats
  202. The endothelin system in human saphenous vein graft disease
  203. [125I]-(Pyr1)Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man
  204. Nitric oxide-mediated modulation of the endothelin-1 signalling pathway in the human cardiovascular system
  205. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1
  206. Endothelin receptor antagonism in patients with chronic heart failure
  207. Urotensin II: fish neuropeptide catches orphan receptor
  208. Preface
  209. Cellular Expression of Isoforms of Endothelin-Converting Enzyme-1 (ECE-1c, ECE-1b and ECE-1a) and Endothelin-Converting Enzyme-2
  210. Changes in ETA-, AT1- and AT2-Receptors in the Phenotypically Transformed Intimal Smooth Muscle Layer of Human Atherosclerotic Coronary Arteries
  211. Endothelin-A-Receptors in Human Aorta and Pulmonary Arteries are Downregulated in Patients With Cardiovascular Disease
  212. Expression and Characterization of the Human Endothelin-A-Receptor in Pichia pastoris
  213. No Alteration in Vasoconstrictor Endothelin-B-Receptor Density or Function in Human Coronary Artery Disease
  214. Novel Nitric Oxide Donors Reverse Endothelin-1-Mediated Constriction in Human Blood Vessels
  215. Syntheses of the First Endothelin-A- and -B-Selective Radioligands for Positron Emission Tomography
  216. Tissue-Specific Modulation of Endothelin Receptors in a Rat Model of Hypertension
  217. Evidence for Intracellular Endothelin-Converting Enzyme-2 Expression in Cultured Human Vascular Endothelial Cells
  218. Blockade and Reversal of Endothelin-Induced Constriction in Pial Arteries From Human Brain   Editorial Comment
  219. Endothelin receptor expression and pharmacology in human saphenous vein graft
  220. Secretory pathways in endothelin synthesis
  221. The therapeutic potential of PD156707 and related butenolide endothelin antagonists
  222. The haemodynamic effects of iodinated water soluble radiographic contrast media: a review
  223. Expression of EndothelinA Receptors in Human Gliomas and Meningiomas, with High Affinity for the Selective Antagonist PD156707
  224. Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease
  225. Human Endothelial Cell Storage Granules : A Novel Intracellular Site for Isoforms of the Endothelin-Converting Enzyme
  226. Endothelin receptor subtypes and their functional relevance in human small coronary arteries
  227. Evidence Using Immunoelectron Microscopy for Regulated and Constitutive Pathways in the Transport and Release of Endothelin
  228. In vitro enzymatic processing of radiolabelled big ET-1 in human kidney
  229. Characterization of [125I]-PD164333, an ETAselective non-peptide radiolabelled antagonist, in normal and diseased human tissues
  230. Characterization of Site-Directed Antisera Against Endothelin-Converting Enzymes
  231. Endothelin Peptide and Converting Enzymes in Human Endothelium
  232. Endothelin-Converting Enzyme in the Human Vasculature: Evidence for Differential Conversion of Big Endothelin-3 by Endothelial and Smooth-Muscle Cells
  233. PD156707: A Potent Antagonist of Endothelin-1 in Human Diseased Coronary Arteries and Vein Grafts
  234. Relative Contribution of Endothelin A and Endothelin B Receptors to Vasoconstriction in Small Arteries from Human Heart and Brain
  235. Endothelin converting enzyme (ECE) activity in human vascular smooth muscle
  236. Detection of Endothelin Receptors in Human Coronary Artery Vascular Smooth Muscle Cells But Not Endothelial Cells by Using Electron Microscope Autoradiography
  237. Differential distribution of endothelin receptor subtypes in placentae from normal and growth-restricted pregnancies
  238. Differential distribution of endothelin peptides and receptors in human adrenal gland
  239. Characterization of the binding of endothelin ETB selective ligands in human and rat heart
  240. Endothelin Peptide and Receptors in Human Atherosclerotic Coronary Artery and Aorta
  241. Selective downregulation of ETA receptor mRNA in renal transplant recipients on cyclosporin A revealed by quantitative RT-PCR
  242. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044
  243. Failure of BQ123, a more potent antagonist of sarafotoxin 6b than of endothelin-1, to distinguish between these agonists in binding experiments
  244. The endothelin system in the kidney
  245. Endothelin receptors in human coronary artery and aorta
  246. Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart
  247. Localization of endothelin peptides in human kidney
  248. Endocrinology and paracrinology
  249. Radioligand Binding Assays: Theory and Practice
  250. Expression of Endothelin Peptides and Mrna in the Human Heart
  251. Endothelin ETA receptor expression in human cerebrovascular smooth muscle cells
  252. Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm
  253. Endothelin expression in the uterus
  254. ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro
  255. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type
  256. ETA and ETB endothelin receptors in human myometrium characterized by the subtype selective ligands BQ123, BQ3020, FR139317 and PD151242
  257. Secretion of endothelin-1 and endothelin-3 by human cultured vascular smooth muscle cells
  258. Selectivity of [125I]-PD 151242 for human, rat and porcine endothelin ETA receptors in the heart
  259. [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature
  260. Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro
  261. Quantification of mRNA in Human Tissue Using Fluorescent Nested Reverse-Transcriptase Polymerase Chain Reaction
  262. Effects of Phosphoramidon and Pepstatin a on the Secretion of Endothelin-I and Big Endothelin-I by Human Umbilical Vein Endothelial Cells: Measurement by Two-Site Enzyme-Linked Immunosorbent Assays
  263. Effects of an ET1-receptor antagonist, FR139317, on regional haemodynamic responses to endothelin-1 and [Ala11,15]Ac-endothelin-1 (6-21) in conscious rats
  264. Davenport and Maguire reply
  265. Validation of mRNA Quantification in Human Kidney by a Novel Fluorescent Nested RT-PCR Method
  266. Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans?
  267. [125I]-PD 151242: a selective radioligand for human ETA receptors
  268. Isolation of Human Cardiac Endothelin Receptors by a Peptide-Receptor Mobility Shift Assay
  269. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney
  270. Alternatively Spliced mRNAs for Human Endothelin-2 and Their Tissue Distribution
  271. Endothelin: progress in pharmacology and physiology
  272. Identification of endothelin-1, endothelin-2 and endothelin-3 in human endometrium
  273. Characterisation of Immunoreactive Endothelin in Human kidney by RP-HPLC and RIA
  274. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium
  275. Quantitative autoradiography reveals higher densities of specific calcitonin-gene-related peptide receptors in small intramyocardial compared with large epicardial coronary arteries
  276. Presence of messenger ribonucleic acid for endothelin-1, endothelin-2, and endothelin-3 in human endometrium and a change in the ratio of ETA and ETB receptor subtype across the menstrual cycle.
  277. Presence of messenger ribonucleic acid for endothelin-1, endothelin-2, and endothelin-3 in human endometrium and a change in the ratio of ETA and ETB receptor subtype across the menstrual cycle
  278. Characterization of two new ETB selective radioligands, [125I]-BQ3020 and [125I]-[Ala1,3,11,15]ET-1 in human heart
  279. Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue
  280. Localization of immunoreactive endothelin and proendothelin in the human lung
  281. Endothelin-like immunoreactivity in human endometrium
  282. Cerebellar neurons and glia respond differentially to endothelins and sarafotoxin S6b
  283. Endothelins in reproduction
  284. Localization and endogenous concentration of endothelin-like immunoreactivity in human placenta
  285. Epidermal growth factor in human endometrium: proliferative effects in culture and immunocytochemical localization in normal and endometriotic tissues
  286. Binding sites for125I ET-1, ET-2, ET-3 and vasoactive intestinal contractor are present in adult rat brain and neurone-enriched primary cultures of embryonic brain cells
  287. Binding sites for iodinated endothelin-1, endothelin-2 and endothelin-3 demonstrated on human uterine glandular epithelial cells by quantitative high-resolution autoradiography
  288. Mitogenic Effects of Vasoactive Peptides on Rat Vascular Smooth Muscle Cells
  289. Endothelin-1 stimulates prostaglandin F2α release from human endometrium
  290. The endothelin peptides ET-1, ET-2, ET-3 and sarafotoxin S6b are co-mitogenic with platelet-derived growth factor for vascular smooth muscle cells
  291. Atrial natriuretic factor mRNA and binding sites in the adrenal gland
  292. Localisation off binding sites for iodinated endothelin and saraffotoxin peptides in mammalian tissues using quantitative receptor autoradiography
  293. Endothelin-1 mRNA is widely expressed in porcine and human tissues.
  294. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: Comparison of levels in patients with essential hypertension and normotensive control subjects
  295. Binding Sites for125I-Labelled Endothelin-1 in the Kidneys: Differential Distribution in Rat, Pig and Man Demonstrated by Using Quantitative Autoradiography
  296. Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway—II. Differential localization of dopamine and cholecystokinin receptors
  297. Comparison between brain paste and polymer [125I]standards for quantitative receptor autoradiography
  298. Effect of the formamidine insecticide chordimeform on feeding and reproduction in the noctuid moth, Spodoptera littoralis (Boisduval)
  299. Quantitative receptor autoradiography
  300. Sex-related differences in the concentration of Met-enkephalin-like immunoreactivity in the nervous system of an insect,Schistocerca gregaria, revealed by radioimmunoassay
  301. Octopamine distribution in the larvae and adults of two species of moth, Spodoptera littoralis and Manduca sexta
  302. The action of formamidines on octopamine receptors in the locust
  303. Toxicity of chlordimeform and amitraz to the egyptian cotton leafworm (Spodoptera littoralis) and the tobacco budworm (Heliothis virescens)
  304. Changes in haemolymph octopamine levels associated with food deprivation in the locust, Schistocerca gregaria
  305. Stress-induced changes in the octopamine levels of insect haemolymph
  306. Biogenic amines in the brain of the honeybee, Apis mellifera
  307. Dynamic In Vivo Imaging of Receptors in Small Animals Using Positron Emission Tomography
  308. Imaging and Characterization of Radioligands for Positron Emission Tomography Using Quantitative Phosphor Imaging Autoradiography
  309. Immunocytochemical Localization of Receptors Using Light and Confocal Microscopy With Application to the Phenotypic Characterization of Knock-Out Mice
  310. Radioligand-Binding and Molecular-Imaging Techniques for the Quantitative Analysis of Established and Emerging Orphan Receptor Systems
  311. Apelins and the Apelin Receptor
  312. Radioligand Binding Assays and Quantitative Autoradiography of Endothelin Receptors
  313. Analysis of Endothelins by Enzyme-Linked Immunosorbent Assay and Radioimmunoassay